Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors

• Status: Terminated
• Trial end date: 2014-11-30
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to evaluate oral doses of BMS-754807 in combination with letrozole or BMS-754807 alone are safe and efficacious in locally advanced or metastatic hormone receptor positive breast cancer subjects who have progressed with prior non-steroidal aromatase inhibitor treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Collaborator: Mayo Clinic
• Treatments: Aromatase Inhibitors; Hormones; Letrozole

Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.

Inclusion Criteria:

• Postmenopausal women with hormone receptor-positive and HER-2 negative breast cancer

• Disease progression following non-steroidal aromatase inhibitor treatment

Exclusion Criteria:

• Known symptomatic brain metastasis

• Medical condition requiring chronic steroids

• History of Type 1 or 2 Diabetes

• Uncontrolled or significant cardiovascular (CV) disease

• Concomitant second malignancies